Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
An immuno-oncology start-up biotech with two candidate anticancer immune-modulating vaccines already in clinical studies, IO Biotech ApS, has attracted new and existing investors to an oversubscribed €127m series B financing, one of the largest in Europe over past months.
Copenhagen, Denmark-based IO Biotech was spun out of the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital...
Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.
